真实世界数据评估 Venetoclax 为基础的方案治疗复发/难治性 t(11;14)多发性骨髓瘤的安全性和疗效。
Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma.
机构信息
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Department of Hematology and Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
出版信息
Br J Haematol. 2020 Jun;189(6):1136-1140. doi: 10.1111/bjh.16454. Epub 2020 Feb 3.
Abstract
The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax-based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non-haematologic toxicities, most commonly gastrointestinal upset, were observed.
摘要
尽管最近有了治疗进展，但复发/难治性多发性骨髓瘤（RRMM）的治疗仍然具有挑战性。 Venetoclax 是一种抗凋亡蛋白 BCL-2 的抑制剂，是一种很有前途的药物，特别是在携带 t(11;14) 的患者中。我们的目的是回顾我们机构中基于 Venetoclax 的方案的经验。所有接受 Venetoclax 治疗的 10 例 RRMM 患者均被纳入研究，且均接受了中位数为 6 线的治疗。总体缓解率为 78%，1 例患有心脏淀粉样变性和 MM 的患者获得了心脏器官缓解。观察到需要输血和血小板的血液学毒性以及最常见的胃肠道不适等非血液学毒性。
相似文献
1
Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma.真实世界数据评估 Venetoclax 为基础的方案治疗复发/难治性 t(11;14)多发性骨髓瘤的安全性和疗效。
Br J Haematol. 2020 Jun;189(6):1136-1140. doi: 10.1111/bjh.16454. Epub 2020 Feb 3.
2
Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.维奈托克在t(11;14)阳性复发/难治性多发性骨髓瘤中的应用：一项系统评价。
J Oncol Pharm Pract. 2024 Apr;30(3):552-561. doi: 10.1177/10781552231218999. Epub 2023 Dec 19.
3
Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma. Venetoclax 和地塞米松靶向治疗复发/难治性 t(11;14)多发性骨髓瘤患者。
Am J Hematol. 2021 Apr 1;96(4):418-427. doi: 10.1002/ajh.26083. Epub 2021 Jan 19.
4
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.维奈托克难治性多发性骨髓瘤患者的自然病史：单中心经验。
Am J Hematol. 2021 Mar 1;96(3):E68-E71. doi: 10.1002/ajh.26064. Epub 2020 Dec 28.
5
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Venetoclax 联合达雷妥尤单抗和地塞米松，加或不加硼替佐米，治疗伴有和不伴有 t(11;14)的复发/难治性多发性骨髓瘤的 I 期研究。
J Clin Oncol. 2021 Nov 10;39(32):3602-3612. doi: 10.1200/JCO.21.00443. Epub 2021 Aug 13.
6
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort.维奈托克联合硼替佐米及地塞米松用于既往接受过大量治疗的无t(11;14)的晚期骨髓瘤患者：一项真实世界队列研究
Hematol Oncol. 2020 Aug;38(3):412-414. doi: 10.1002/hon.2736. Epub 2020 Apr 23.
7
Venetoclax monotherapy induced rapid and sustained response in a frail patient with refractory AL amyloidosis: Less is more?维奈托克单药治疗在一位虚弱的难治性 AL 淀粉样变性患者中诱导出快速和持续的缓解：少即是多？
Int J Hematol. 2020 Aug;112(2):234-237. doi: 10.1007/s12185-020-02857-2. Epub 2020 Mar 23.
8
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.尽管有负面试验，但 Venetoclax 在 t(11;14)多发性骨髓瘤中的持续成功。
Oncology (Williston Park). 2024 Jun 10;38(6):239-241. doi: 10.46883/2024.25921023.
9
Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence.伴有 t(11;14)相关性幼稚表型的多发性骨髓瘤 CD38 表达较低，BCL2 依赖性较高。
Cancer Sci. 2021 Sep;112(9):3645-3654. doi: 10.1111/cas.15073. Epub 2021 Jul 29.
10
Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Venetoclax 敏感性与多发性骨髓瘤中的 B 细胞基因表达有关。
Blood. 2021 Jul 1;137(26):3604-3615. doi: 10.1182/blood.2020007899.
引用本文的文献
1
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).伴有 t(6;14)易位的复发/难治性多发性骨髓瘤患者中有效的维奈托克治疗。
Pathol Oncol Res. 2023 Nov 10;29:1611375. doi: 10.3389/pore.2023.1611375. eCollection 2023.
2
Venetoclax salvage therapy in relapsed/refractory multiple myeloma.维奈托克挽救疗法用于复发/难治性多发性骨髓瘤
Haematologica. 2024 Mar 1;109(3):979-981. doi: 10.3324/haematol.2023.283472.
3
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis.基于维奈托克的方案治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项系统评价和荟萃分析。
Ther Adv Hematol. 2023 Mar 6;14:20406207231155028. doi: 10.1177/20406207231155028. eCollection 2023.
4
Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.探索伴有t(11;14)易位的多发性骨髓瘤患者的当前分子格局及管理。
Front Oncol. 2022 Aug 2;12:934008. doi: 10.3389/fonc.2022.934008. eCollection 2022.
5
A same-day assay predicts apoptotic response to combined BCL-2 and MCL-1 BH3-mimetic targeting in multiple myeloma cells.一种当日检测方法可预测多发性骨髓瘤细胞对联合靶向 BCL-2 和 MCL-1 的 BH3 模拟物的凋亡反应。
EJHaem. 2020 Nov 20;2(1):40-47. doi: 10.1002/jha2.133. eCollection 2021 Feb.
6
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results.多发性骨髓瘤患者临床试验之外：真实世界结果的批判性综述
Front Oncol. 2022 May 11;12:844779. doi: 10.3389/fonc.2022.844779. eCollection 2022.
7
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.靶向 Venetoclax 治疗 t(11;14)多发性骨髓瘤：来自七个匈牙利中心的真实世界数据。
Pathol Oncol Res. 2022 Feb 28;28:1610276. doi: 10.3389/pore.2022.1610276. eCollection 2022.
8
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.复发和/或难治性多发性骨髓瘤（MM）的变化态势：基础与争议
Biomark Res. 2022 Jan 9;10(1):1. doi: 10.1186/s40364-021-00344-2.
9
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.多发性骨髓瘤治疗中免疫治疗之外的新型方法：美法仑氟芬、维奈克拉和塞利尼索的案例
Front Oncol. 2021 Sep 30;11:716751. doi: 10.3389/fonc.2021.716751. eCollection 2021.
10
Role of Venetoclax in the Treatment of Relapsed and Refractory Multiple Myeloma.维奈托克在复发难治性多发性骨髓瘤治疗中的作用
J Hematol. 2021 Jun;10(3):89-97. doi: 10.14740/jh844. Epub 2021 Jun 16.
本文引用的文献
1
The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.维奈托克、达雷妥尤单抗和地塞米松联合用于治疗难治性原发性浆细胞白血病。
Am J Hematol. 2020 Feb;95(2):E34-E35. doi: 10.1002/ajh.25676. Epub 2019 Dec 2.
2
Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).单药维奈托克在复发的伴有t(11;14)的原发性浆细胞白血病中诱导微小残留病阴性反应。
Am J Hematol. 2019 Jan;94(1):E35-E37. doi: 10.1002/ajh.25331. Epub 2018 Nov 25.
3
Targeting Bcl-2 for the treatment of multiple myeloma.针对 Bcl-2 治疗多发性骨髓瘤。
Leukemia. 2018 Sep;32(9):1899-1907. doi: 10.1038/s41375-018-0223-9. Epub 2018 Aug 3.
4
Venetoclax: A new wave in hematooncology.维奈托克：血液肿瘤学的新潮流。
Exp Hematol. 2018 May;61:10-25. doi: 10.1016/j.exphem.2018.02.002. Epub 2018 Mar 2.
5
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.复发和难治性多发性骨髓瘤的治疗：新型药物、抗体、免疫疗法及其他。
Leukemia. 2018 Feb;32(2):252-262. doi: 10.1038/leu.2017.329. Epub 2017 Nov 16.
6
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Venetoclax 作为靶向治疗复发/难治性 t(11;14)多发性骨髓瘤的疗效。
Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.
7
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.硼替佐米和地塞米松联合维奈托克治疗复发/难治性多发性骨髓瘤显示出良好的疗效和可接受的安全性。
Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.
8
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.复发多发性骨髓瘤的自然史，对免疫调节剂和蛋白酶体抑制剂耐药：一项多中心 IMWG 研究。
Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.
9
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.国际骨髓瘤工作组多发性骨髓瘤反应和微小残留病评估的共识标准。
Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
10
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.BCL-2、BCL-XL和MCL-1的表达谱预测多发性骨髓瘤模型对BCL-2选择性拮抗剂维奈托克的药理反应。
Mol Cancer Ther. 2016 May;15(5):1132-44. doi: 10.1158/1535-7163.MCT-15-0730. Epub 2016 Mar 3.
Zotero 插件